---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-034688"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2023-10-19T23:59:59+00:00"
generated_at: "2026-06-09T21:00:35.420445+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcutis pre-announces Q3 revenue of $38.1M; ZORYVE approved for pediatric psoriasis

## Summary
- Preliminary Q3 2023 total revenue of $38.1M: $8.1M net product revenue (ZORYVE) and $30M other revenue from Huadong Medicine license.
- Cash, equivalents, and marketable securities of $228.1M as of Sep 30, 2023.
- FDA approved ZORYVE (roflumilast) cream 0.3% for plaque psoriasis in children ages 6-11, including intertriginous areas.
- Positive topline data from INTEGUMENT-PED and INTEGUMENT-OLE trials for atopic dermatitis in pediatric patients.
- Company implemented headcount reductions to align with pipeline reprioritization and improve financial flexibility.

## SEC filing metadata
- accession: 0001628280-23-034688
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2023-10-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000162828023034688/0001628280-23-034688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000162828023034688/arqt-20231019.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-034688
- JSON: https://secwatch.observer/filing/0001628280-23-034688.json
- Plain text: https://secwatch.observer/filing/0001628280-23-034688.txt

## Key facts
- Earnings Releases
  Arcutis Biotherapeutics, Inc. reported three months ended September 30, 2023 results: revenue total revenues of approximately $38.1 million, which comprised net product revenue of approximately $8.1 million and oth.
  - Period: three months ended September 30, 2023
  - Revenue: total revenues of approximately $38.1 million, which comprised net product revenue of approximately $8.1 million and oth
  - Result: preliminary results
  source text: While the Company has not finalized its full financial results as of and for the quarter ended September 30, 2023, the Company expects to report that for the three months ended September 30, 2023, the Company generated total revenues of approximately $38.1 million, which comprised net product revenue of approximately $8.1 million and other revenue of $30.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000162828023034688/0001628280-23-034688-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.